X4 Pharmaceuticals, Inc XFOR

Rank #2444 · Nasdaq · $0.3B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

18.2

P/E

-3.1

P/B

4.27

ROE

-136.6%

Op. Margin

–%

Debt Ratio

168%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -3.1x, P/B 4.27x. Ranks in the top 77% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -136.6%. Ranks in the top 96% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 168%. Ranks in the top 57% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	-695.6	-66
2019	–	$-0.0B	$-0.0B	$-0.0B	–	-94
2020	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-71
2021	$0.0B	$-0.1B	$-0.1B	$-0.1B	–	-65
2022	$0.0B	$-0.1B	$-0.1B	$0.1B	-1995.8	41
2023	–	$-0.1B	$-0.1B	$0.1B	–	112
2024	$0.0B	$-0.1B	$-0.1B	$0.1B	–	149
2025	$0.0B	$-0.1B	$-0.1B	$0.1B	–	168

← See the full screener